Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

New advice on strontium ranelate

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a press release noting that updated advice will be distributed to healthcare professionals regarding strontium ranelate (Protelos®) which is used to treat severe osteoporosis in post-menopausal women and men with a high risk of fracture.

A review was conducted by the European Medicines Agency recently because of study data which suggested an increased risk of heart problems. The review concluded there is no increased risk in individuals who have no history of heart or circulatory problems. However, in individuals who do have a history of heart or circulatory problems strontium is now only recommended if they are unable to take alternative medicines.

This advice will be disseminated to healthcare professionals via letter and will also be included in the March edition of the Drug Safety Update.

Action: Clinicians should be aware of this new advice. This change in advice would make a good topic for an audit.

Share 'New advice on strontium ranelate' on Email Share 'New advice on strontium ranelate' on Delicious Share 'New advice on strontium ranelate' on Digg Share 'New advice on strontium ranelate' on Facebook Share 'New advice on strontium ranelate' on Google+ Share 'New advice on strontium ranelate' on reddit Share 'New advice on strontium ranelate' on StumbleUpon Share 'New advice on strontium ranelate' on Twitter

atomic-wealth

No Comments to “New advice on strontium ranelate”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,316 spam comments.

atomic-wealth
fond-illness
summer